# OnCo record sympatico (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/sympatico/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "sympatico", "NCT03112174" ;
  schema:name "SYMPATICO"@en ;
  schema:alternateName "PCYC-1143-CA"@en ;
  schema:description "SYMPATICO showed that adding the BCL2 blocker venetoclax to ibrutinib for people whose mantle cell lymphoma had returned kept the disease under control for about ten months longer than ibrutinib alone, and the combination also produced complete responses in most untreated patients with the hard-to-treat TP53 mutation."@en ;
  schema:url <https://onco.cc/trials/sympatico/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03112174>, <https://clinicaltrials.gov/study/NCT03112174?tab=results> ;
  onco:status "positive" ;
  onco:tag "soc-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/venetoclax/> ;
  onco:companies <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/johnson-johnson/> .